Please login to the form below

Not currently logged in
Email:
Password:

filibuvir

This page shows the latest filibuvir news and features for those working in and with pharma, biotech and healthcare.

AbbVie gets 'breakthrough' status for hepatitis C regimen

AbbVie gets 'breakthrough' status for hepatitis C regimen

In March Pfizer dropped HCV candidate filibuvir after a strategic review of its pipeline, while last year BMS abandoned its polymerase inhibitor BMS-986094 candidate after a patient death in trials.

Latest news

  • Pfizer drops hepatitis C candidate filibuvir Pfizer drops hepatitis C candidate filibuvir

    pipeline. The decision to drop filibuvir, reported by the Wall Street Journal on Friday, effectively means that Pfizer has withdrawn from the race to develop a non-interferon-based regimen for ... Filibuvir (also known as PF-00868554) is a non-nucleoside

  • HCV hope on the horizon

    Tibotec). . Among the polymerase inhibitors, the most advanced in development is Pfizer's non-nucleoside compound filibuvir at phase II.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics